Henry Ford Health enrolled the first US patients in a global clinical trial evaluating pulmonary artery denervation for pulmonary hypertension related to heart disease. The study expands access to a procedural approach designed to modulate sympathetic signaling believed to contribute to disease physiology. Pulmonary hypertension remains a high-morbidity condition with limited options for patients whose disease is linked to left-heart pathology. Adding the US site indicates the denervation strategy is moving deeper into pragmatic, multi-region evaluation. The initiation also signals growing interest in non-pharmacologic interventions alongside existing drug classes, with device-led trials likely to demand clear endpoints around hemodynamics, functional capacity, and safety in real-world populations.